Trever Burnett, MD
Allergy & Immunology · Yakima, WANPI 1134100423
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 274 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AstraZeneca at 27.4% of the total. 2025 is the largest year on record at $2,468, more than ten times the $53 reported in 2019.
Across 274 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$693
- Regeneron Healthcare Solutions, Inc.$597
- GSK$493
- Takeda Pharmaceuticals U.S.A., Inc.$274
- Pharming Healthcare, Inc.$256
- plus $2K from 25 others
What the payments were for
- Consulting fees$1282%
- Food & beverage$6,08095%
- Education$1863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 67 | $1,753 |
| Sanofi | 39 | $693 |
| Regeneron Healthcare Solutions, Inc. | 25 | $597 |
| GSK | 22 | $493 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $274 |
| Pharming Healthcare, Inc. | 13 | $256 |
| Sanofi-aventis U.S. LLC | 2 | $250 |
| Novartis | 12 | $243 |
| CSL Behring | 11 | $228 |
| Blueprint Medicines Corporation | 6 | $228 |
| Biocryst US Sales Co., LLC | 10 | $188 |
| Pfizer | 6 | $130 |
| ADMA Biomanufacturing LLC | 6 | $128 |
| Amgen | 5 | $119 |
| Lilly USA, LLC | 5 | $107 |
| Genentech USA, Inc. | 4 | $98 |
| Verona Pharma, Inc. | 4 | $97 |
| Alk-abello, Inc | 4 | $92 |
| Ionis Pharmaceuticals, Inc. | 2 | $67 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $67 |
| Viatris Specialty LLC | 2 | $52 |
| AbbVie | 2 | $37 |
| Dermavant Sciences, Inc. | 1 | $32 |
| Incyte Corporation | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| LEO Pharma Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Organon | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,394 in reported general payments places this provider in the 70th percentile of 81 allergy & immunology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 36 | $111,896 |
| TezspireTezepelumab-Ekko | 16 | $70,855 |
| Dupixent SyringeDupilumab | 13 | $57,382 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $49,503 |
| Dupixent PenDupilumab | 13 | $48,498 |
| Advair HfaFluticasone Propion/Salmeterol | 72 | $37,449 |
| Spiriva RespimatTiotropium Bromide | 49 | $33,716 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $33,103 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 155 | $26,621 |
| Arnuity ElliptaFluticasone Furoate | 44 | $17,180 |
| Spiriva HandihalerTiotropium Bromide | 19 | $15,760 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $15,721 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $11,795 |
| DuleraMometasone/Formoterol | 20 | $11,194 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $9,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $493 | $107,878157 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,753 | $98,37186 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $17 | $43,13664 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $25 | $6,43217 claims |
| Alk-abello, IncGrastek | $92 | $5,44911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 81 allergy & immunology providers in Washington.
Other allergy & immunology in Yakima
- Taiil SongLakewood$192K
- Frank VirantSeattle$107K
- Richard GowerSpokane$104K
- Leonard AltmanSeattle$81K
- Daniel PetroniSeattle$68K
- David McGarrySpokane Valley$66K
- Rahool DaveSeattle$42K
- David ElkayamBellingham$39K
- Matthew AltmanSeattle$37K
- Arthur VeghTacoma$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.